Shilpa Medicare Limited (NSE:SHILPAMED)
827.60
-9.05 (-1.08%)
Sep 12, 2025, 3:29 PM IST
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 3.21B INR in the quarter ending June 30, 2025, with 9.90% growth. This brings the company's revenue in the last twelve months to 13.15B, up 11.10% year-over-year. In the fiscal year ending March 31, 2025, Shilpa Medicare had annual revenue of 12.88B with 11.69% growth.
Revenue (ttm)
13.15B
Revenue Growth
+11.10%
P/S Ratio
6.15
Revenue / Employee
13.18M
Employees
998
Market Cap
80.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 12.88B | 1.35B | 11.69% |
Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
Mar 31, 2021 | 9.02B | -66.41M | -0.73% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Shilpa Medicare News
- 15 days ago - Shilpa Medicare jumps another 2.5% as stock extends rally on Saudi JV announcement - Business Upturn
- 16 days ago - Shilpa Medicare shares jump 2% after its subsidiary forms JV with Saudi Pharma giant PPI - Business Upturn
- 16 days ago - Shilpa Medicare subsidiary forms strategic JV with Saudi Pharma giant PPI - Business Upturn
- 4 weeks ago - Shilpa Medicare Q1 Results: Revenue rises 9.9% to Rs 321 crore, Net profit jumps over 3x YoY - Business Upturn
- 4 weeks ago - Shilpa Medicare shares jump 3% after CDSCO approval for NorUDCA tablets - Business Upturn
- 5 weeks ago - Shilpa Medicare gets CDSCO approval for NorUDCA tablets 500 mg, marks first global clearance for NAFLD treatment - Business Upturn
- 2 months ago - Shilpa Medicare shares jump nearly 5% after USFDA issues EIR with VAI for Bengaluru unit - Business Upturn
- 2 months ago - Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations - Business Upturn